Tocqueville Asset Management L.P. Neu Base Therapeutics, Inc. Transaction History

Tocqueville Asset Management L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.41 - $1.3 $4,510 - $14,300	-11,000 Reduced 20.56%	42,500 $17,000
Q4 2021 Feb 14, 2022	SELL	$2.6 - $4.18 $53,300 - $85,690	-20,500 Reduced 27.7%	53,500 $150,000
Q3 2021 Nov 15, 2021	BUY	$3.27 - $4.76 $147,804 - $215,152	45,200 Added 156.94%	74,000 $267,000
Q2 2021 Aug 16, 2021	SELL	$4.63 - $7.34 $82,182 - $130,285	-17,750 Reduced 38.13%	28,800 $138,000
Q1 2021 May 17, 2021	SELL	$6.92 - $12.36 $38,060 - $67,980	-5,500 Reduced 10.57%	46,550 $344,000
Q4 2020 Feb 16, 2021	BUY	$6.92 - $9.25 $219,364 - $293,225	31,700 Added 155.77%	52,050 $364,000
Q3 2020 Nov 16, 2020	BUY	$7.25 - $9.71 $147,537 - $197,598	20,350 New	20,350 $154,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Tocqueville Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on Tocqueville Asset Management L.P. with notifications on news.